EpithalaminЭпиталамин
A pineal-gland extract containing a mixture of peptides, studied in human aging and melatonin research.
What the studies found
Comparison in people · 2011
Epithalamin and 15-year follow-up in older adults with coronary disease
- Alive at 15 years
- 26/39 (66.7%) vs 16/40 (40.0%)Epithalamin plus standard care versus standard care.
- Deaths attributed to myocardial infarction or stroke
- 6/13 deaths vs 20/24 deathsCause-of-death counts among participants who died.
At 15 years, 26/39 patients in the Epithalamin group and 16/40 in the standard-care group were alive. This small historical comparison followed patients with coronary disease.
Study notes · methods, sources and limitations
Participants or model 79 older patients with coronary disease. Thirty-nine received adjunctive Epithalamin and 40 received standard care alone.
Design Reported randomized comparative follow-up from the Kyiv gerontology program with survival curves and cardiovascular outcomes.
Important limitations
- Small historical comparison, with limited reporting about masking and subsequent treatment. The associated 12-year paper may share the same participants. Epithalamin is a pineal extract. The study did not administer synthetic Epitalon.
Bulletin of Experimental Biology and Medicine. 2011;151(3):366–369. PMID 22451889. · Publication record
Comparison in people · 2008
Epithalamin after complicated appendicitis
Study of multiple preparations
- Mean hospitalization
- 18.0 ± 0.6 daysAdjunct sample: 12. Standard care: 24.2 ± 0.6 days (n = 10).
- TNF-α before → after
- 486 ± 28 → 205 ± 19 pg/mL (n = 12)Within-group p < 0.001 in Table 3
In this small comparison, mean stay was 6.2 days shorter with Epithalamin plus standard care. The standard-care group averaged 24.2 days.
Author affiliations · Chita Medical Institute
Study notes · methods, sources and limitations
Participants or model 84 adults aged 18–42: 12 with uncomplicated appendicitis and 72 with postoperative wound infection. Of the 72, 62 received a peptide adjunct. Thirty healthy volunteers were a laboratory reference group.
Design Comparison of standard care and peptide adjuncts after postoperative wound infection. The paper measured serum cytokines by immunoassay and compared immune markers before and after treatment.
Important limitations
- The study had small, unequal groups and unclear treatment assignment. The differences are unadjusted.
- Small, unequal groups and unclear treatment assignment leave confounding unresolved. The article does not establish that Vilon was superior or equivalent to the other adjuncts. The Vilon hospital groups totaled 40. The cytokine table included 25, with no breakdown by treatment duration. The hospitalization paragraph prints p < 0.01 after each mean without clearly specifying a contrast. No systematic adverse-event table or quantified wound-healing rates were recovered.
- Vilon showed the largest within-group TNF-α decrease. Hospitalization means were close among the four adjunct groups. Neither outcome establishes a comparative treatment effect.
Medical Immunology. 2008;10(4–5):455–462. · Original clinical journal article
Animal research · 2012
Melatonin and pineal gland peptides are able to correct the impairment of reproductive cycles in rats
Study of multiple preparations
- Epithalamin
- Recovery of norepinephrine diurnal dynamics in medial preoptic areaNorepinephrine decreased between 09:30 and 11:00 circadian time
- Epitalon
- Dopamine remained low at 05:00 and increased by 11:00 circadian timeMedian eminence/arcuate region; no numerical concentrations supplied
- Pregnancy and fertility outcomes
- No pregnant cohort, congenital-anomaly rate or verified live-birth benefit in the abstract
Epithalamin reportedly restored hypothalamic norepinephrine rhythms, while Epitalon had a stronger dopamine-rhythm effect in another hypothalamic region. The experiment used 1,2-dimethylhydrazine, not a pregnancy model or a methionine-only intervention.
Study notes · methods, sources and limitations
Participants or model Nonpregnant female rats in a xenobiotic-induced reproductive-aging model; n absent from abstract
Design Single 1,2-dimethylhydrazine exposure in female rats; region- and circadian-time-specific catecholamine measurements after melatonin or pineal-peptide interventions.
Important limitations
- Reproductive-cycle neurochemistry is not pregnancy-safety evidence or proof of improved human fertility.
- Reproductive-cycle neurochemistry is not pregnancy-safety evidence or proof of improved human fertility. Epitalon is a defined tetrapeptide; Epithalamin is a bovine pineal peptide extract. Their findings are not interchangeable. Doses, n, allocation, quantitative effect sizes and adverse-event surveillance unavailable in the abstract.
Current aging science. 2012;5(3):178-85. PMID 23237594 · Original journal publication
About Epithalamin
Names in this research collection
Epithalamine
Organ-derived peptide research: clinical findings and lineage ↗
Research background
A pineal-gland tissue extract containing a mixture of peptides. Human aging and melatonin studies of this preparation must be distinguished from research on synthetic Epitalon (AEDG).
Pregnancy and offspring research
Epithalamin reportedly restored hypothalamic norepinephrine rhythms, while Epitalon had a stronger dopamine-rhythm effect in another hypothalamic region. The experiment used 1,2-dimethylhydrazine, not a pregnancy model or a methionine-only intervention.
Reproductive-cycle neurochemistry is not pregnancy-safety evidence or proof of improved human fertility.
Reported findings and methods ↗ · Pregnancy research: full evidence review and archive ↗
More study findings
Animal research · 2018
Original hypoxia, heat and cold results
Study of multiple preparations
- Epithalamin · course hypoxia and cold
- 7.4±4.5 min at 10 mg/kg in hypoxia; 194±22 vs 168±12 min at 0.5 mg/kg in air coolingSeparate dose and stress protocols. 1 mg/kg hypoxia arm was unmarked.Both selected contrasts p<0.05 as marked
- Publication overlap
- 2014 Table 11 and 2018 Table 1 repeat the same valuesCounts as one reported experiment. Both publications also describe a distinct acute mouse screen.
The 2014 and 2018 course-hypoxia tables repeat the same experiment.
Study notes · methods, sources and limitations
Participants or model Outbred male mice in the single-dose hypoxia screen; male rats (180–210 g) in the repeated-dose hypoxia table. Separate temperature experiments.
Design The single-dose mouse screen used 10,000 m, 8–10 per dose in the 2018 report (6–10 in the 2014 book). Table 1 instead reports a three-day rat series tested at 11,500 m the next day. Arm sizes for the repeated-dose table are not stated in the audited passage.
Important limitations
- Separate mouse and rat protocols. Human performance was not assessed.
- The 2018 rat course results and 2014 book table belong to one evidence family. The book omits an explicit course-series species and altitude in the adjacent paragraph. Short survival in an extreme animal model is separate from human endurance or safety.
- The papers distinguish the single-dose mouse screen from the three-day rat protocol. The matching table adds no independent animals or human participants.
Biomeditsina 2018(2):4–14, Tables 1–3; paired with 2014 Volume III Table 11 · Biomeditsina 2018(2):4–14, Tables 1–3; paired with 2014 Volume III Table 11
Comparison in people · 2014
Single intranasal exposure at simulated altitude
Study of multiple preparations
- Epithalamin · number of complaints
- 0.33±0.13 vs 1.4±0.5Authors marked a trend.p<0.1 versus saline
Table 12 compares four small peptide arms with saline at 4,500 m.
Study notes · methods, sources and limitations
Participants or model Men aged 20–25 with asthenic or immune-status features. Four active arms of 6–8 each and 11 saline controls.
Design Author-described random assignment. Exposure for 60–80 min at simulated 4,500 m with postural testing, a three-minute 100 W cycling load, motor tasks and blood measurements.
Important limitations
- Participant overlap with the broader aerospace archive remains unresolved.
- Small arms, numerous endpoints and several comparisons reported at p<0.1. Exact allocation counts and overlap with the Medilab lineage remain unresolved.
- The 4,500 m protocol differs from Cheprasov’s 5,000 m comparison. Participant independence has not been established and this series adds no people to the historical tally.
Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 7, pp. 177–180, Table 12 · Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 7, pp. 177–180, Table 12
Comparison in people · 1997
Cheprasov’s Medilab peptide comparisons in aerospace stress
Study of multiple preparations
- Hypobaric comparison
- Thymalin: 15–20% higher work measures; Cortexin: 10–15% improvement in selected operator measuresAbstract narrative; full arm-level estimates unavailable.
- Coriolis motion tolerance
- Cortexin +89%, Thymogen +73%, Epithalamin +68%Reported tolerance-time improvement relative to control, ten per arm.
- Sustained work
- Author reported recovery of selected Thymogen-group measures to baseline by three hoursFour per arm. Cortexin and oral Bemitil plus sydnocarb were separate comparators.
The three test series covered hypoxia, motion tolerance and 24 hours of work. The abstract reports favorable task results for selected peptides and gives a tiny separate postflight Thymogen comparison.
More reported outcomes
- Postflight respiratory infections
- 1 of 4 in Thymogen arm versus 4 of 4 salineReported during the following year, a descriptive count from four pairs.
- Program headcount
- 328 stated; stage rows add to 338The 116 and 8 are subseries, with no additional headcount contributed to the historical tally.
Study notes · methods, sources and limitations
Participants or model 116 men across three stress comparisons (30, 70 and 16), plus an eight-cosmonaut comparison within the reported dissertation program of 328.
Design Hypobaric test: three arms of 10 at 5,000 m for 60 min. Motion: seven arms of 10 in a Coriolis test. Work: four arms of four at 50% of individually tolerated load. Postflight: four mission pairs, one participant per pair given Thymogen.
- Reported study exposure
- Hypoxia: intranasal Cortexin or Thymalin, 20 mg per course over two days, or placebo. Motion: single intranasal 5 mg Thymalin, Cortexin, Prostatilen or Epithalamin, or 50 µg Thymogen, with oral scopolamine 0.1 mg and placebo controls. Work: nasal Thymogen 100 µg or Cortexin 10 mg before work and after 6 and 12 h, or oral sydnocarb plus Bemitil, or saline. Postflight: intranasal Thymogen 100 µg/day for seven days.
Important limitations
- Small comparisons, incomplete outcome reporting and unclear separation from related Medilab publications.
- Small comparisons, incomplete outcome reporting and unclear separation from related Medilab publications. The 47 modeling experts were outside the participant table.
- The aerospace findings concern separate stress and recovery tasks, with no reliable pooled treatment effect.
Kirov Military Medical Academy doctoral dissertation author abstract, Table 1 and methods · Kirov Military Medical Academy doctoral dissertation author abstract, Table 1 and methods
Animal research · 2006
Age and baseline anxiety in Lysenko’s peptide stress models
Study of multiple preparations
- High-anxiety young rats
- Vilon and GVS-111 were highlighted in the author’s conclusionsOriginal group-level numerical estimates and doses still need retrieval.
- Stress-response direction
- Favorable and unfavorable responses describedThe author discusses this for GVS-111 and an experimental preparation called NKT. NKT identity remains unresolved.
The author reported that the direction of peptide-associated changes depended on age and baseline anxiety. Some shifts were unfavorable.
Study notes · methods, sources and limitations
Participants or model Rats grouped by age and baseline anxiety; series-specific denominators remain unverified.
Design Hypokinesia, hypoxia and exertion models, with behavioral, immune and oxidative endpoints. Twenty-four-hour hypokinesia was one stress protocol.
Important limitations
- Potential overlap with narrower author-network dissertations, including Morgul and Rudenko. Outcomes cannot be pooled or assigned to humans.
- A mechanistic program on stress response. The dissertation-level conclusion does not isolate all preparation-specific effects.
Doctoral dissertation, 244 pp., introduction and conclusions · Doctoral dissertation, 244 pp., introduction and conclusions
Animal research · 2004
Epithalamin under exercise and restricted movement in younger and older rats
- Age × stressor pattern
- Stronger reported responses in young rats during exhaustive loading; in old rats during restricted movementQualitative comparison in dissertation conclusions.
- Baseline behavior
- Lower locomotor activity and food intake described after EpithalaminReported in unstressed animals; a different endpoint from stress adaptation.
- Biological measures
- Leukocyte, lipid-peroxidation and blood-cell membrane changes reportedDifferent markers and conditions; no numerical treatment effect extracted.
The author reports stronger Epithalamin-associated stress-marker responses during exhaustive exercise in younger animals, and during restricted movement in older animals.
Study notes · methods, sources and limitations
Participants or model Younger and older rats; baseline, exhaustive physical loading and restricted-movement series
Design Younger and older rats; baseline, exhaustive physical loading and restricted-movement series
Important limitations
- Exact dose and effect estimates require full methods and original outcome tables.
- Exact dose and effect estimates require full methods and original outcome tables. Changes in behavior, lipid peroxidation and leukocyte profiles are not proof of increased athletic endurance.
- The age and stressor matter. These results apply to the studied extract, with no demonstrated benefit in athletes.
Candidate dissertation, Saint Petersburg, 2004 · Dissertation
Animal research · 2012
Epithalamin and melatonin in rat brain during acute hypoxia
- Hippocampal malondialdehyde
- 27.30 ± 3.28 vs 35.60 ± 3.90 vs 52.90 ± 2.36 µmol/gEpithalamin + hypoxia, melatonin + hypoxia and hypoxia alone, respectively.
- Hippocampal neutral protein oxidation products
- 2.290 ± 0.205 vs 3.740 ± 0.274 vs 2.960 ± 0.136Same three groups. Units are mmol hydrazones/g protein.
- Cortical neutral protein oxidation products
- 3.560 ± 0.162 vs 2.520 ± 0.367 vs 3.500 ± 0.206Same three groups. The Epithalamin result was close to hypoxia alone.
Under simulated 12,000 m hypoxia, hippocampal malondialdehyde was 27.3 µmol/g with Epithalamin, 35.6 with melatonin and 52.9 with hypoxia alone. Epithalamin reduced hippocampal protein oxidation but did not reduce cortical protein oxidation in the same pattern.
Study notes · methods, sources and limitations
Participants or model 97 young outbred male rats in the overall study. Both tables say n = 7, and the methods describe pooling tissue from two animals per suspension.
Design Six conditions included vehicle control, melatonin, Epithalamin, hypoxia alone and each drug before hypoxia. Rats of medium hypoxia resistance were used after prescreening. The chamber simulated 12,000 m until the second agonal inspiration. Cortex and hippocampus were analyzed separately.
Important limitations
- The overall animal total cannot be allocated to arms from the table labels alone. The reported significance labels do not establish an Epithalamin-versus-melatonin comparison. These are brain tissue biomarkers after an acute challenge. The study used the pineal extract Epithalamin and did not test synthetic AEDG (Epitalon).
Bulletin of Experimental Biology and Medicine. 2012;154(1):51–53. PMID 23330089. · Publication record
Observational study · 2004
Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people
Reported changes in nighttime melatonin that differed according to baseline pineal activity.
Study notes · methods, sources and limitations
Participants or model Older adults; plasma melatonin before and after treatment
Important limitations
- Before/after hormone measurements do not establish sleep-stage or clinical sleep benefit. The preparation is Epithalamin, not isolated AEDG.
Bull Exp Biol Med 137(4):389-391. PMID 15452611 · Indexed abstract
Randomized study in people · 2006
Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging
- All-cause deaths
- 28% fewer in the treated group as reported
- Cardiovascular mortality
- Twofold lower as reported
- Cardiovascular failure and respiratory disease incidence
- Twofold lower as reported
The abstract describes a randomized comparison and reports favorable long-term cardiovascular and mortality outcomes with the pineal extract.
Study notes · methods, sources and limitations
Participants or model Older patients with coronary disease and accelerated cardiovascular aging; 12-year follow-up
Design Twelve-year report involving elderly coronary-disease patients, described as randomized; Epithalamin tissue extract plus basic care versus basic care.
Important limitations
- The abstract leaves group assignment and follow-up unclear and gives no absolute event counts. Potential overlap with later follow-up reports must be checked; this is not an Epitalon trial.
- No sample size, event counts or confidence intervals are supplied in the abstract. These are Epithalamin extract findings, not synthetic Epitalon results.
Bull Exp Biol Med 142(3):356-359. PMID 17426848 · Indexed abstract
Review of earlier studies · 2026
Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence.
Study of multiple preparations
This 2026 review separates synthetic Epitalon from the pineal extract Epithalamin. It brings together work on telomeres, circadian rhythms and cellular aging, while finding that clinical benefit and long-term safety still need stronger human studies.
Study notes · methods, sources and limitations
Participants or model Narrative review of experimental and human literature through 22 September 2026
Important limitations
- Narrative synthesis, not a new experiment or a pooled estimate of treatment benefit. Epithalamin extract findings cannot be assigned directly to synthetic Epitalon.
International journal of molecular sciences · Indexed abstract
Performance research in context
- Compound class
- Tissue-derived polypeptide complex
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- St. Petersburg Institute of Bioregulation and Gerontology · Chita Medical Institute
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Clinical reports linked; see study-specific limitations
Study methods
Original reports separated from narrative reviews and patents
Independent replication
Independent replication not established by this collection
Source access
Linked abstracts, analytical papers, reviews and patents; individual scope shown below
Safety evidence
Incomplete assessment; findings do not establish safety for personal use
Open a topic for the evidence assessment.
Patents and claimed inventions
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Comparison in people · 2011
Epithalamin and 15-year follow-up in older adults with coronary disease
At 15 years, 26/39 patients in the Epithalamin group and 16/40 in the standard-care group were alive. This small historical comparison followed patients with coronary disease.
Alive at 15 years · 26/39 (66.7%) vs 16/40 (40.0%) · Epithalamin plus standard care versus standard care.
Study notes and original source
Epithalamin and 15-year follow-up in older adults with coronary disease
O. V. Korkushko, V. Kh. Khavinson, V. B. Shatilo, I. A. Antoniuk-Shcheglova · Bulletin of Experimental Biology and Medicine. 2011;151(3):366–369. PMID 22451889.
At 15 years, 26/39 patients in the Epithalamin group and 16/40 in the standard-care group were alive. This small historical comparison followed patients with coronary disease.
Results and tables
Reported findings and study design
Reported randomized comparative follow-up from the Kyiv gerontology program with survival curves and cardiovascular outcomes.
Population or model 79 older patients with coronary disease. Thirty-nine received adjunctive Epithalamin and 40 received standard care alone.
Dose, route and schedule
10 mg in 2 mL saline intramuscularly every third morning, five injections per course (50 mg per course). Six courses at six-month intervals over the first three years, with basic therapy. The 15-year result is follow-up after that treatment period.
Protocol source ↗ · Original English paper and indexed Russian-program publications. Compared with an earlier 12-year report and a Palermo conference citation.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Alive at 15 years | 26/39 (66.7%) vs 16/40 (40.0%) | Epithalamin plus standard care versus standard care. |
| Deaths attributed to myocardial infarction or stroke | 6/13 deaths vs 20/24 deaths | Cause-of-death counts among participants who died. |
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 79 older patients with coronary disease. Thirty-nine received adjunctive Epithalamin and 40 received standard care alone.
- Source reviewed
- Original English paper and indexed Russian-program publications. Compared with an earlier 12-year report and a Palermo conference citation.
Study limitations
- Small historical comparison, with limited reporting about masking and subsequent treatment. The associated 12-year paper may share the same participants.
- Epithalamin is a pineal extract. The study did not administer synthetic Epitalon.
Reviewed 2026-11-14.
Animal research · 2018
Thymogen and four peptide preparations in hypoxia, heat and cold
The 2014 and 2018 course-hypoxia tables repeat the same experiment.
Study notes and original source
Thymogen and four peptide preparations in hypoxia, heat and cold
· Biomeditsina 2018(2):4–14, Tables 1–3; paired with 2014 Volume III Table 11
Format: Original 2018 methods and Tables 1–3 compared with Volume III Chapter 7, pp. 174–177. · Reviewed: Reported methods, results and evidence limitations
E. B. Shustov, M. T. Gasanov, G. D. Kapanadze, Yu. V. Fokin, V. S. Novikov, E. L. Matveenko, Kh. Kh. Semenov · Biomeditsina 2018(2):4–14, Tables 1–3; paired with 2014 Volume III Table 11
In the three-day rat comparison, Thymogen at 0.1 mg/kg gave 28.6±11.8 min versus 2.2±0.1 with saline. All 16 arms and their reported values match the 2014 monograph. Thymogen had no significant benefit on the air-cooling endpoint.
Results and tables
Reported findings and study design
In the three-day rat comparison, Thymogen at 0.1 mg/kg gave 28.6±11.8 min versus 2.2±0.1 with saline. All 16 arms and their reported values match the 2014 monograph. Thymogen had no significant benefit on the air-cooling endpoint.
The single-dose mouse screen used 10,000 m, 8–10 per dose in the 2018 report (6–10 in the 2014 book). Table 1 instead reports a three-day rat series tested at 11,500 m the next day. Arm sizes for the repeated-dose table are not stated in the audited passage.
Population or model Outbred male mice in the single-dose hypoxia screen; male rats (180–210 g) in the repeated-dose hypoxia table. Separate temperature experiments.
Dose, route and schedule
Historical animal protocol. Intraperitoneal dosing daily for three days for the course hypoxia series. Thymogen 0.001, 0.01 or 0.1 mg/kg, with distinct dose ranges for the other preparations.
Protocol source ↗ · Original 2018 methods and Tables 1–3 compared with Volume III Chapter 7, pp. 174–177.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Thymogen · course hypoxia | 10.6±3.2, 20.1±11.1 and 28.6±11.8 min | At 0.001, 0.01 and 0.1 mg/kg respectively. Saline 2.2±0.1 min. · p<0.05, p<0.01 and p<0.01 versus saline as marked. |
| Thymalin · course hypoxia | 7.1±2.6 min at 0.1 mg/kg versus 2.2±0.1 min saline | 0.5 mg/kg arm was unmarked for significance. · p<0.05 for 0.1 mg/kg |
| Cortexin · course hypoxia and heat | 5.2±3.2 min at 1 mg/kg in hypoxia; 88.6±2.4 vs 96.5±5.2 min at 5 mg/kg in heat | Separate stress experiments and different doses. The heat endpoint shortened. · Both selected contrasts p<0.05 as marked |
| Prostatilen · course hypoxia | 7.0±5.6 min at 0.1 mg/kg versus 2.2±0.1 min saline | At 0.5 mg/kg: 4.2±0.7 min and a 66% increase in resistant animals as printed. · 0.1 mg/kg time p<0.01 as marked |
| Epithalamin · course hypoxia and cold | 7.4±4.5 min at 10 mg/kg in hypoxia; 194±22 vs 168±12 min at 0.5 mg/kg in air cooling | Separate dose and stress protocols. 1 mg/kg hypoxia arm was unmarked. · Both selected contrasts p<0.05 as marked |
| Thymogen · air cooling | 185±25 vs 168±12 min to rectal temperature of 35°C | 0.05 mg/kg versus control. No significant contrast marked. |
| Publication overlap | 2014 Table 11 and 2018 Table 1 repeat the same values | Counts as one reported experiment. Both publications also describe a distinct acute mouse screen. |
Matched course-hypoxia data · 2014 Table 11 and 2018 Table 1
| Arm | Dose (mg/kg unless noted) | Time (min) | Reported change (%) | Resistant-animal share increase (%) |
|---|---|---|---|---|
| Saline | 1.0 as printed | 2.2±0.1 | 0 | 0 |
| Thymalin | 0.1 | 7.1±2.6* | 238 | 38 |
| Thymalin | 0.5 | 3.7±1.0 | 76 | 16 |
| Thymalin | 1.0 | 4.4±2.2* | 110 | 16 |
| Cortexin | 0.1 | 3.9±1.4 | 86 | 5 |
| Cortexin | 0.5 | 3.8±0.4* | 81 | 16 |
| Cortexin | 1.0 | 5.2±3.2* | 148 | 5 |
| Prostatilen | 0.1 | 7.0±5.6** | 233 | 0 |
| Prostatilen | 0.5 | 4.2±0.7* | 100 | 66* |
| Prostatilen | 1.0 | 2.4±1.0 | 14 | 16 |
| Epithalamin | 0.1 | 2.7±0.6 | 22 | 15 |
| Epithalamin | 1.0 | 1.8±0.5 | 0 | 0 |
| Epithalamin | 10.0 | 7.4±4.5* | 236 | 33 |
| Thymogen | 0.001 | 10.6±3.2* | 405 | 48* |
| Thymogen | 0.01 | 20.1±11.1** | 857 | 60* |
| Thymogen | 0.1 | 28.6±11.8** | 1262 | 80** |
M±m. * p<0.05, ** p<0.01 versus saline. Percentage column transcribed as printed and may differ from calculations using rounded means. The book’s adjacent mouse protocol describes the acute screen.
The papers distinguish the single-dose mouse screen from the three-day rat protocol. The matching table adds no independent animals or human participants.
Source for these results ↗ · Reviewed 2026-11-09
- Population / setting
- Outbred male mice in the single-dose hypoxia screen; male rats (180–210 g) in the repeated-dose hypoxia table. Separate temperature experiments.
- Source reviewed
- Original 2018 methods and Tables 1–3 compared with Volume III Chapter 7, pp. 174–177.
Study limitations
- The 2018 rat course results and 2014 book table belong to one evidence family. The book omits an explicit course-series species and altitude in the adjacent paragraph.
- Short survival in an extreme animal model is separate from human endurance or safety.
Reviewed 2026-11-09.
Comparison in people · 2014
Four intranasal peptide arms at simulated 4,500 m
Table 12 compares four small peptide arms with saline at 4,500 m.
Study notes and original source
Four intranasal peptide arms at simulated 4,500 m
· Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 7, pp. 177–180, Table 12
Format: Original publication and selected methods and results checked · Reviewed: Reported methods, results and evidence limitations
N. N. Karkishchenko, V. V. Uyba, V. N. Karkishchenko, E. B. Shustov, K. V. Kotenko, S. L. Lyublinskiy · Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 7, pp. 177–180, Table 12
Thymogen was associated with lower lactate during the chamber protocol. Cortexin showed longer complex reaction latency alongside other physiological changes. The endpoints were heterogeneous.
Results and tables
Reported findings and study design
Thymogen was associated with lower lactate during the chamber protocol. Cortexin showed longer complex reaction latency alongside other physiological changes. The endpoints were heterogeneous.
Author-described random assignment. Exposure for 60–80 min at simulated 4,500 m with postural testing, a three-minute 100 W cycling load, motor tasks and blood measurements.
Population or model Men aged 20–25 with asthenic or immune-status features. Four active arms of 6–8 each and 11 saline controls.
Dose, route and schedule
Single intranasal administration one hour before ascent: Thymogen 1 µg, Cortexin 10 mg, Epithalamin 10 mg or Prostatilen 5 mg. The control received equivalent-volume saline.
Protocol source ↗ · Original publication and selected methods and results checked
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Thymogen · blood lactate | 1.81±0.21 vs 2.98±0.46 | Source Table 12 units not specified on the row. · p<0.05 versus saline |
| Cortexin · complex visuomotor reaction latency | 423±12 vs 381±9 ms | Slower response, even with some favorable markers. · p<0.01 versus saline |
| Epithalamin · number of complaints | 0.33±0.13 vs 1.4±0.5 | Authors marked a trend. · p<0.1 versus saline |
| Prostatilen · number of complaints | 0.2±0.2 vs 1.4±0.5 | Small short-term comparison. · p<0.05 versus saline |
The 4,500 m protocol differs from Cheprasov’s 5,000 m comparison. Participant independence has not been established and this series adds no people to the historical tally.
Source for these results ↗ · Reviewed 2026-11-09
- Population / setting
- Men aged 20–25 with asthenic or immune-status features. Four active arms of 6–8 each and 11 saline controls.
- Source reviewed
- Original publication and selected methods and results checked
Study limitations
- Small arms, numerous endpoints and several comparisons reported at p<0.1. Exact allocation counts and overlap with the Medilab lineage remain unresolved.
Reviewed 2026-11-09.
Comparison in people · 1997
Cheprasov’s Medilab peptide comparisons in aerospace stress
The three test series covered hypoxia, motion tolerance and 24 hours of work. The abstract reports favorable task results for selected peptides and gives a tiny separate postflight Thymogen comparison.
Study notes and original source
Cheprasov’s Medilab peptide comparisons in aerospace stress
· Kirov Military Medical Academy doctoral dissertation author abstract, Table 1 and methods
Format: Author’s abstract transcription. Full dissertation and underlying records unavailable. · Reviewed: Reported methods, results and evidence limitations
V. V. Cheprasov · Kirov Military Medical Academy doctoral dissertation author abstract, Table 1 and methods
The three test series covered hypoxia, motion tolerance and 24 hours of work. The abstract reports favorable task results for selected peptides and gives a tiny separate postflight Thymogen comparison.
Results and tables
Reported findings and study design
The three test series covered hypoxia, motion tolerance and 24 hours of work. The abstract reports favorable task results for selected peptides and gives a tiny separate postflight Thymogen comparison.
Hypobaric test: three arms of 10 at 5,000 m for 60 min. Motion: seven arms of 10 in a Coriolis test. Work: four arms of four at 50% of individually tolerated load. Postflight: four mission pairs, one participant per pair given Thymogen.
Population or model 116 men across three stress comparisons (30, 70 and 16), plus an eight-cosmonaut comparison within the reported dissertation program of 328.
Dose, route and schedule
Hypoxia: intranasal Cortexin or Thymalin, 20 mg per course over two days, or placebo. Motion: single intranasal 5 mg Thymalin, Cortexin, Prostatilen or Epithalamin, or 50 µg Thymogen, with oral scopolamine 0.1 mg and placebo controls. Work: nasal Thymogen 100 µg or Cortexin 10 mg before work and after 6 and 12 h, or oral sydnocarb plus Bemitil, or saline. Postflight: intranasal Thymogen 100 µg/day for seven days.
Protocol source ↗ · Author’s abstract transcription. Full dissertation and underlying records unavailable.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Hypobaric comparison | Thymalin: 15–20% higher work measures; Cortexin: 10–15% improvement in selected operator measures | Abstract narrative; full arm-level estimates unavailable. |
| Coriolis motion tolerance | Cortexin +89%, Thymogen +73%, Epithalamin +68% | Reported tolerance-time improvement relative to control, ten per arm. |
| Sustained work | Author reported recovery of selected Thymogen-group measures to baseline by three hours | Four per arm. Cortexin and oral Bemitil plus sydnocarb were separate comparators. |
| Postflight respiratory infections | 1 of 4 in Thymogen arm versus 4 of 4 saline | Reported during the following year, a descriptive count from four pairs. |
| Program headcount | 328 stated; stage rows add to 338 | The 116 and 8 are subseries, with no additional headcount contributed to the historical tally. |
The aerospace findings concern separate stress and recovery tasks, with no reliable pooled treatment effect.
Source for these results ↗ · Reviewed 2026-11-09
- Population / setting
- 116 men across three stress comparisons (30, 70 and 16), plus an eight-cosmonaut comparison within the reported dissertation program of 328.
- Source reviewed
- Author’s abstract transcription. Full dissertation and underlying records unavailable.
Study limitations
- Small comparisons, incomplete outcome reporting and unclear separation from related Medilab publications.
- The 47 modeling experts were outside the participant table.
Reviewed 2026-11-09.
Animal research · 2006
Age and baseline anxiety in Lysenko’s peptide stress models
The author reported that the direction of peptide-associated changes depended on age and baseline anxiety. Some shifts were unfavorable.
Study notes and original source
Age and baseline anxiety in Lysenko’s peptide stress models
· Doctoral dissertation, 244 pp., introduction and conclusions
Format: Author’s abstract transcription. Full dissertation and underlying records unavailable. · Reviewed: Reported methods, results and evidence limitations
A. V. Lysenko · Doctoral dissertation, 244 pp., introduction and conclusions
The author reported that the direction of peptide-associated changes depended on age and baseline anxiety. Some shifts were unfavorable.
Results and tables
Reported findings and study design
The author reported that the direction of peptide-associated changes depended on age and baseline anxiety. Some shifts were unfavorable.
Hypokinesia, hypoxia and exertion models, with behavioral, immune and oxidative endpoints. Twenty-four-hour hypokinesia was one stress protocol.
Population or model Rats grouped by age and baseline anxiety; series-specific denominators remain unverified.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| High-anxiety young rats | Vilon and GVS-111 were highlighted in the author’s conclusions | Original group-level numerical estimates and doses still need retrieval. |
| Stress-response direction | Favorable and unfavorable responses described | The author discusses this for GVS-111 and an experimental preparation called NKT. NKT identity remains unresolved. |
A mechanistic program on stress response. The dissertation-level conclusion does not isolate all preparation-specific effects.
Source for these results ↗ · Reviewed 2026-11-09
- Population / setting
- Rats grouped by age and baseline anxiety; series-specific denominators remain unverified.
- Source reviewed
- Author’s abstract transcription. Full dissertation and underlying records unavailable.
Study limitations
- Potential overlap with narrower author-network dissertations, including Morgul and Rudenko. Outcomes cannot be pooled or assigned to humans.
Reviewed 2026-11-09.
Animal research · 2004
Epithalamin under exercise and restricted movement in younger and older rats
The author reports stronger Epithalamin-associated stress-marker responses during exhaustive exercise in younger animals, and during restricted movement in older animals.
Study notes and original source
Epithalamin under exercise and restricted movement in younger and older rats
Epithalamin pineal extract; distinct from Epitalon, Pinealon and Pineamin. · Dissertation
Format: Accessible dissertation or author-abstract transcription; full scan and original tables not recovered · Reviewed: Reported methods, results and evidence limitations
T. N. Rudenko · Candidate dissertation, Saint Petersburg, 2004
The author reports stronger Epithalamin-associated stress-marker responses during exhaustive exercise in younger animals, and during restricted movement in older animals.
Results and tables
Reported findings and study design
The author reports stronger Epithalamin-associated stress-marker responses during exhaustive exercise in younger animals, and during restricted movement in older animals.
Younger and older rats; baseline, exhaustive physical loading and restricted-movement series
Population or model Younger and older rats; baseline, exhaustive physical loading and restricted-movement series
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Age × stressor pattern | Stronger reported responses in young rats during exhaustive loading; in old rats during restricted movement | Qualitative comparison in dissertation conclusions. |
| Baseline behavior | Lower locomotor activity and food intake described after Epithalamin | Reported in unstressed animals; a different endpoint from stress adaptation. |
| Biological measures | Leukocyte, lipid-peroxidation and blood-cell membrane changes reported | Different markers and conditions; no numerical treatment effect extracted. |
The age and stressor matter. These results apply to the studied extract, with no demonstrated benefit in athletes.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Younger and older rats; baseline, exhaustive physical loading and restricted-movement series
- Source reviewed
- Accessible dissertation or author-abstract transcription; full scan and original tables not recovered
Study limitations
- Exact dose and effect estimates require full methods and original outcome tables.
- Changes in behavior, lipid peroxidation and leukocyte profiles are not proof of increased athletic endurance.
Reviewed 2026-11-08.
Animal research · 2012
Melatonin and pineal gland peptides are able to correct the impairment of reproductive cycles in rats
Epithalamin reportedly restored hypothalamic norepinephrine rhythms, while Epitalon had a stronger dopamine-rhythm effect in another hypothalamic region. The experiment used 1,2-dimethylhydrazine, not a pregnancy model or a methionine-only intervention.
Study notes and original source
Melatonin and pineal gland peptides are able to correct the impairment of reproductive cycles in rats
Epitalon (Ala-Glu-Asp-Gly), Epithalamin pineal extract and melatonin in separate comparisons · Original journal publication
Format: Publication record and available text · Reviewed: Indexed original abstract; full methods and outcome tables not recovered
Arutjunyan A, Kozina L, Milyutina Y, Korenevsky A, Stepanov M, Arutyunov V · Current aging science. 2012;5(3):178-85. PMID 23237594
Epithalamin reportedly restored hypothalamic norepinephrine rhythms, while Epitalon had a stronger dopamine-rhythm effect in another hypothalamic region. The experiment used 1,2-dimethylhydrazine, not a pregnancy model or a methionine-only intervention.
Results and tables
Reported findings and study design
Findings described in words
Epithalamin reportedly restored hypothalamic norepinephrine rhythms, while Epitalon had a stronger dopamine-rhythm effect in another hypothalamic region. The experiment used 1,2-dimethylhydrazine, not a pregnancy model or a methionine-only intervention.
Single 1,2-dimethylhydrazine exposure in female rats; region- and circadian-time-specific catecholamine measurements after melatonin or pineal-peptide interventions.
Population or model Nonpregnant female rats in a xenobiotic-induced reproductive-aging model; n absent from abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Epithalamin | Recovery of norepinephrine diurnal dynamics in medial preoptic area | Norepinephrine decreased between 09:30 and 11:00 circadian time |
| Epitalon | Dopamine remained low at 05:00 and increased by 11:00 circadian time | Median eminence/arcuate region; no numerical concentrations supplied |
| Pregnancy and fertility outcomes | No pregnant cohort, congenital-anomaly rate or verified live-birth benefit in the abstract |
Reproductive-cycle neurochemistry is not pregnancy-safety evidence or proof of improved human fertility. Epitalon is a defined tetrapeptide; Epithalamin is a bovine pineal peptide extract. Their findings are not interchangeable. Doses, n, allocation, quantitative effect sizes and adverse-event surveillance unavailable in the abstract.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Nonpregnant female rats in a xenobiotic-induced reproductive-aging model; n absent from abstract
- Source reviewed
- Indexed original abstract; full methods and outcome tables not recovered
Study limitations
- Reproductive-cycle neurochemistry is not pregnancy-safety evidence or proof of improved human fertility.
- Epitalon is a defined tetrapeptide; Epithalamin is a bovine pineal peptide extract. Their findings are not interchangeable.
- Doses, n, allocation, quantitative effect sizes and adverse-event surveillance unavailable in the abstract.
Reviewed 2026-11-08.
Comparison in people · 2008
Thymalin, Epithalamin and Vilon after complicated appendicitis
In this small comparison, mean stay was 6.2 days shorter with Epithalamin plus standard care. The standard-care group averaged 24.2 days.
Study notes and original source
Thymalin, Epithalamin and Vilon after complicated appendicitis
Author affiliations · Chita Medical Institute
· Original clinical journal article
B. I. Kuznik, Kh. R. Abdulaev, Yu. A. Vitkovsky, I. D. Likhanov, M. N. Tsybikov, N. N. Tsybikov · Medical Immunology. 2008;10(4–5):455–462.
Mean hospital stay was 24.2 days with standard care and 18.0–19.0 days in the four adjunct groups. TNF-α fell most in the Vilon cytokine subset. IL-8 increased in every measured group.
Results and tables
Reported findings and study design
Comparison of standard care and peptide adjuncts after postoperative wound infection. The paper measured serum cytokines by immunoassay and compared immune markers before and after treatment.
Population or model 84 adults aged 18–42: 12 with uncomplicated appendicitis and 72 with postoperative wound infection. Of the 72, 62 received a peptide adjunct. Thirty healthy volunteers were a laboratory reference group.
Dose, route and schedule
Standard care included abscess drainage, antibiotics and symptomatic treatment. The reported adjuncts were intramuscular Thymalin or Epithalamin at 10 mg per injection for 10 days, or Vilon at 10 µg per injection for five or ten days.
Protocol source ↗ · Original article, pp. 455–456
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Mean hospitalization | 24.2 days with standard care versus 18.0–19.0 days with peptide adjuncts | Unadjusted group means from five small, unequal groups. |
| TNF-α in the Vilon cytokine subset | 447 ± 20 to 115 ± 9 pg/mL (n = 25) | Within-group p < 0.001 in Table 3 |
| IL-8 | Rose in all four cytokine groups, including standard care. | |
| Wound closure and safety | The authors described primary wound healing. No arm-level wound-healing rate or systematic adverse-event table was recovered. |
Reported hospital stay by treatment group
| Group | Patients | Mean days ± reported uncertainty | Difference from standard care |
|---|---|---|---|
| Standard care | 10 | 24.2 ± 0.6 | Reference |
| Thymalin | 10 | 19.0 ± 0.7 | 5.2 days shorter |
| Epithalamin | 12 | 18.0 ± 0.6 | 6.2 days shorter |
| Vilon, five days | 30 | 18.8 ± 0.6 | 5.4 days shorter |
| Vilon, ten days | 10 | 19.0 ± 0.5 | 5.2 days shorter |
Differences are calculated from published means. The paper does not clearly identify the contrast for the p-values printed alongside these means.
Table 3: serum cytokines before → after treatment
| Cytokine (pg/mL) | Healthy reference | Standard care (n = 10) | Thymalin (n = 10) | Epithalamin (n = 12) | Vilon (n = 25) |
|---|---|---|---|---|---|
| TNF-α | 13 ± 4 | 432 ± 32 → 389 ± 25 | 396 ± 28 → 186 ± 21 | 486 ± 28 → 205 ± 19 | 447 ± 20 → 115 ± 9 |
| IL-8 | 18 ± 5 | 126 ± 18 → 678 ± 31 | 146 ± 20 → 383 ± 24 | 159 ± 19 → 453 ± 28 | 175 ± 16 → 418 ± 25 |
| IL-1α | 12 ± 3 | 105 ± 28 → 88 ± 15 | 123 ± 21 → 58 ± 12 | 135 ± 20 → 87 ± 14 | 131 ± 11 → 52 ± 6 |
| IL-1β | 8 ± 2 | 368 ± 24 → 142 ± 19 | 326 ± 23 → 245 ± 24 | 310 ± 22 → 318 ± 25 | Not reported |
Mean ± standard error as labeled in the PDF. TNF-α within-group p > 0.05 with standard care and p < 0.001 in each adjunct group. Vilon’s cytokine subset is distinct from its 40-person hospital-stay comparison. Values follow the original PDF text where digital transcriptions disagree.
Vilon showed the largest within-group TNF-α decrease. Hospitalization means were close among the four adjunct groups. Neither outcome establishes a comparative treatment effect.
Source for these results ↗ · Reviewed 2026-11-10
- Population / setting
- 84 adults aged 18–42: 12 with uncomplicated appendicitis and 72 with postoperative wound infection. Of the 72, 62 received a peptide adjunct. Thirty healthy volunteers were a laboratory reference group.
- Source reviewed
- Original journal PDF text, methods and Tables 1 and 3 checked. The 321st District Military Clinical Hospital in Chita was an author affiliation.
Study limitations
- Small, unequal groups and unclear treatment assignment leave confounding unresolved. The article does not establish that Vilon was superior or equivalent to the other adjuncts.
- The Vilon hospital groups totaled 40. The cytokine table included 25, with no breakdown by treatment duration.
- The hospitalization paragraph prints p < 0.01 after each mean without clearly specifying a contrast. No systematic adverse-event table or quantified wound-healing rates were recovered.
Reviewed 2026-11-10.
Animal research · 2012
Epithalamin and melatonin in rat brain during acute hypoxia
Under simulated 12,000 m hypoxia, hippocampal malondialdehyde was 27.3 µmol/g with Epithalamin, 35.6 with melatonin and 52.9 with hypoxia alone. Epithalamin reduced hippocampal protein oxidation but did not reduce cortical protein oxidation in the same pattern.
Hippocampal malondialdehyde · 27.30 ± 3.28 vs 35.60 ± 3.90 vs 52.90 ± 2.36 µmol/g · Epithalamin + hypoxia, melatonin + hypoxia and hypoxia alone, respectively.
Study notes and original source
Epithalamin and melatonin in rat brain during acute hypoxia
I. I. Zamorskii, I. Yu. Sopova, V. Kh. Khavinson · Bulletin of Experimental Biology and Medicine. 2012;154(1):51–53. PMID 23330089.
Under simulated 12,000 m hypoxia, hippocampal malondialdehyde was 27.3 µmol/g with Epithalamin, 35.6 with melatonin and 52.9 with hypoxia alone. Epithalamin reduced hippocampal protein oxidation but did not reduce cortical protein oxidation in the same pattern.
Results and tables
Reported findings and study design
Reported findings
Six conditions included vehicle control, melatonin, Epithalamin, hypoxia alone and each drug before hypoxia. Rats of medium hypoxia resistance were used after prescreening. The chamber simulated 12,000 m until the second agonal inspiration. Cortex and hippocampus were analyzed separately.
Population or model 97 young outbred male rats in the overall study. Both tables say n = 7, and the methods describe pooling tissue from two animals per suspension.
Dose, route and schedule
Epithalamin 2.5 mg/kg or melatonin 1 mg/kg was injected intraperitoneally 30 minutes before simulated altitude exposure. Separate arms received the preparations in normoxia. Tissue was collected 30 minutes after acute hypoxia.
Protocol source ↗ · Original article Methods
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Hippocampal malondialdehyde | 27.30 ± 3.28 vs 35.60 ± 3.90 vs 52.90 ± 2.36 µmol/g | Epithalamin + hypoxia, melatonin + hypoxia and hypoxia alone, respectively. |
| Hippocampal neutral protein oxidation products | 2.290 ± 0.205 vs 3.740 ± 0.274 vs 2.960 ± 0.136 | Same three groups. Units are mmol hydrazones/g protein. |
| Cortical neutral protein oxidation products | 3.560 ± 0.162 vs 2.520 ± 0.367 vs 3.500 ± 0.206 | Same three groups. The Epithalamin result was close to hypoxia alone. |
Malondialdehyde by region, Table 2 (µmol/g tissue)
| Exposure | Cortex | Hippocampus |
|---|---|---|
| Control | 46.50 ± 1.61 | 45.50 ± 1.35 |
| Hypoxia | 54.10 ± 1.83 | 52.90 ± 2.36 |
| Melatonin | 43.10 ± 1.46 | 36.00 ± 1.29 |
| Epithalamin | 38.60 ± 1.29 | 34.70 ± 4.72 |
| Melatonin + hypoxia | 38.80 ± 1.34 | 35.60 ± 3.90 |
| Epithalamin + hypoxia | 38.50 ± 1.31 | 27.30 ± 3.28 |
Mean ± error as printed (M ± m, table n = 7). These values are tissue markers rather than measures of neuronal survival.
Source for these results ↗ · Reviewed 2026-11-11
- Population / setting
- 97 young outbred male rats in the overall study. Both tables say n = 7, and the methods describe pooling tissue from two animals per suspension.
- Source reviewed
- Complete translated article, methods and both printed tables visually checked.
Study limitations
- The overall animal total cannot be allocated to arms from the table labels alone.
- The reported significance labels do not establish an Epithalamin-versus-melatonin comparison.
- These are brain tissue biomarkers after an acute challenge. The study used the pineal extract Epithalamin and did not test synthetic AEDG (Epitalon).
Reviewed 2026-11-11.
Experiment described in a patent · 2001
Pineal extracts: manufacturing and composition patent — RU2163129C1
The disclosed extract was associated with lower reported glucose measures over 12 weeks, without a verified product-specific Epithalamin match.
Fasting glycemia · Reported decreases of 15%, 22% and 29.4% from baseline · Treated group; baseline glucose values and modern allocation details not extracted · Weeks 2, 4 and 12
Study notes and original source
Pineal extracts: manufacturing and composition patent — RU2163129C1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
В.Х. Хавинсон, В.Г. Морозов, В.И. Семенова, О.В. Чайка, Г.А. Рыжак · RU2163129C1 · patent family 20236906
The disclosed extract was associated with lower reported glucose measures over 12 weeks, without a verified product-specific Epithalamin match.
Results and tables
Reported patent results
Reported findings
The disclosed extract was associated with lower reported glucose measures over 12 weeks, without a verified product-specific Epithalamin match.
Pineal-extract patent includes a type-2-diabetes clinical comparison: 33 treated patients and a 24-person control group.
Population or model Pineal-extract patent includes a type-2-diabetes clinical comparison: 33 treated patients and a 24-person control group.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Fasting glycemia | Reported decreases of 15%, 22% and 29.4% from baseline | Treated group; baseline glucose values and modern allocation details not extracted · Weeks 2, 4 and 12 |
| Postprandial glycemia | Reported decreases of 18.2%, 28% and 41% | Not absolute glucose concentrations · Weeks 2, 4 and 12 |
| Control and HbA1c | No significant control-group glycemic change; treated HbA1c described as decreased without an extracted numerical value | No invented HbA1c effect size |
Concurrent diabetes care, incompletely specified allocation and patent reporting prevent a causal estimate. The extract is not synthetic AEDG; commercial Epithalamin equivalence and longevity benefit are unproven.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Pineal-extract patent includes a type-2-diabetes clinical comparison: 33 treated patients and a 24-person control group.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- A product-specific match to commercial Epithalamin was not established. This tissue-complex patent is not the defined AEDG Epitalon molecular patent, nor proof of human longevity.
- Concurrent diabetes care, incompletely specified allocation and patent reporting prevent a causal estimate. The extract is not synthetic AEDG; commercial Epithalamin equivalence and longevity benefit are unproven.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Review of earlier studies · 2026
Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence.
This 2026 review separates synthetic Epitalon from the pineal extract Epithalamin. It brings together work on telomeres, circadian rhythms and cellular aging, while finding that clinical benefit and long-term safety still need stronger human studies.
Study notes and original source
Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence.
Jain A, Gallacher DM, Issa MA, Deer TR, Yong RJ, Diwan S, Lee W, Sayed D, Amirdelfan K, Robinson CL · International journal of molecular sciences
This 2026 review separates synthetic Epitalon from the pineal extract Epithalamin. It brings together work on telomeres, circadian rhythms and cellular aging, while finding that clinical benefit and long-term safety still need stronger human studies.
- Population / setting
- Narrative review of experimental and human literature through 22 September 2026
- Source reviewed
- Publication metadata and indexed abstract checked through Europe PMC on 28 October 2026; full text not appraised.
Study limitations
- Narrative synthesis, not a new experiment or a pooled estimate of treatment benefit.
- Epithalamin extract findings cannot be assigned directly to synthetic Epitalon.
Reviewed 2026-10-28.
Research record · 2003
Эффективность применения пептидных биорегуляторов у лиц разного возраста в условиях Крайнего Севера — Effectiveness of peptide bioregulators in people of different ages under Far North conditions
The dissertation trail links examinations of Gazprom employees and family members to the program approved in February 2000. Indexed recommendations name sequential Thymalin, Epithalamin and Cortexin for a disease-specific setting; they do not establish a universal occupational regimen.
Study notes and original source
Эффективность применения пептидных биорегуляторов у лиц разного возраста в условиях Крайнего Севера — Effectiveness of peptide bioregulators in people of different ages under Far North conditions
Thymalin, Epithalamin and Cortexin tissue-derived preparations · Dissertation record and indexed excerpts
Vladimir Alekseevich Cherkashin · Candidate of Medical Sciences dissertation, St. Petersburg, 2003; 203 pages
The dissertation trail links examinations of Gazprom employees and family members to the program approved in February 2000. Indexed recommendations name sequential Thymalin, Epithalamin and Cortexin for a disease-specific setting; they do not establish a universal occupational regimen.
- Population / setting
- Far North clinical research associated with Gazprom employees and families; exact cohort allocation unresolved
- Source reviewed
- Available sources include bibliographic metadata and dissertation excerpts. The complete thesis was unavailable for review.
Study limitations
- Full 203-page dissertation has not been obtained.
- Search-indexed excerpts are not a substitute for original methods and tables.
- Named sequential therapy for dyscirculatory encephalopathy does not identify treatment for every Gazprom employee.
- Overlap with the broader program and other clinical cohorts remains unresolved.
Reviewed 2026-10-02.
Review of earlier studies · 2013
Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results
Summarizes clinical work on seven named peptide preparations. Useful for tracing original Russian reports and distinguishing tissue extracts from short peptides.
Study notes and original source
Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results
Khavinson VKh, Kuznik BI, Ryzhak GA · Adv Gerontol 26(1):20-37. PMID 24003726
Summarizes clinical work on seven named peptide preparations. Useful for tracing original Russian reports and distinguishing tissue extracts from short peptides.
- Population / setting
- Originating group’s clinical and gerontology literature
- Source reviewed
- Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
- Review by investigators in the originating program; not independent replication.
- Clinical findings must be traced to the exact preparation and original study.
Reviewed 2026-09-29.
Laboratory analysis · 2017
Identification of Peptide AEDG in the Polypeptide Complex of the Pineal Gland
Mass spectrometry/HPLC and selective reaction monitoring identified AEDG in the pineal complex. This supplies a molecular link to the synthetic tetrapeptide.
Study notes and original source
Identification of Peptide AEDG in the Polypeptide Complex of the Pineal Gland
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Khavinson VK, Kopylov AT, Vaskovsky BV, Ryzhak GA, Lin'kova NS · Bull Exp Biol Med 164(1):41-43. PMID 29124531
Mass spectrometry/HPLC and selective reaction monitoring identified AEDG in the pineal complex. This supplies a molecular link to the synthetic tetrapeptide.
Results and tables
Reported findings and study design
HPLC/mass-spectrometry analysis of pineal polypeptide complex; AEDG identified among tetrapeptides.
Population or model Pineal polypeptide-complex composition
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Free amino acids | 3.26% | |
| Dipeptides | 23.19% | |
| Tripeptides | 50.72% | |
| Tetrapeptides | 22.10% | |
| Pentapeptides | 0.72% |
These are composition fractions of the complex, not AEDG concentration or bioavailability. Detection of AEDG does not make extract clinical results interchangeable with synthetic Epitalon.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Pineal polypeptide-complex composition
- Source reviewed
- Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
- Detection in an extract does not prove that this peptide accounts for all extract effects.
- Composition analysis does not establish clinical equivalence.
Reviewed 2026-09-29.
Comparison in people · 2003
Peptides of pineal gland and thymus prolong human life
The investigators reported differences in illness and mortality across extract-treatment groups and controls. This is research on Thymalin and Epithalamin, including their combination.
Study notes and original source
Peptides of pineal gland and thymus prolong human life
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Khavinson VKh, Morozov VG · Neuro Endocrinol Lett 24(3-4):233-240. PMID 14523363
The investigators reported differences in illness and mortality across extract-treatment groups and controls. This is research on Thymalin and Epithalamin, including their combination.
Results and tables
Reported findings and study design
266 older adults followed 6–8 years; Thymalin/Epithalamin used during the first 2–3 years. A separate annual-combination subgroup was treated for six years.
Population or model 266 older people followed for 6–8 years
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Acute respiratory disease incidence | Two- to 2.4-fold lower as reported | |
| Mortality, Thymalin group | Two- to 2.1-fold lower | |
| Mortality, Epithalamin group | 1.6- to 1.8-fold lower | |
| Mortality, combination group | 2.5-fold lower | |
| Separate annual-combination subgroup mortality | 4.1-fold lower |
Source abstract does not supply arm denominators, death counts or confidence intervals. Separate treatment schedules are not pooled and extract results are not assigned to synthetic peptides.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 266 older people followed for 6–8 years
- Source reviewed
- Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
- The abstract leaves group assignment, dropouts, baseline differences and outcome assessment unclear.
- The outcomes concern the preparations used in this study. Independent replication and effects of Vilon, Thymogen and synthetic Epitalon remain uncertain.
Reviewed 2026-09-29.
Observational study · 2004
Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people
Reported changes in nighttime melatonin that differed according to baseline pineal activity.
Study notes and original source
Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people
Korkushko OV, Khavinson VKh, Shatilo VB, Magdich LV · Bull Exp Biol Med 137(4):389-391. PMID 15452611
Reported changes in nighttime melatonin that differed according to baseline pineal activity.
- Population / setting
- Older adults; plasma melatonin before and after treatment
- Source reviewed
- Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
- Before/after hormone measurements do not establish sleep-stage or clinical sleep benefit.
- The preparation is Epithalamin, not isolated AEDG.
Reviewed 2026-09-29.
Randomized study in people · 2006
Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging
The abstract describes a randomized comparison and reports favorable long-term cardiovascular and mortality outcomes with the pineal extract.
All-cause deaths · 28% fewer in the treated group as reported
Study notes and original source
Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging
Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA · Bull Exp Biol Med 142(3):356-359. PMID 17426848
The abstract describes a randomized comparison and reports favorable long-term cardiovascular and mortality outcomes with the pineal extract.
Results and tables
Reported findings and study design
Twelve-year report involving elderly coronary-disease patients, described as randomized; Epithalamin tissue extract plus basic care versus basic care.
Population or model Older patients with coronary disease and accelerated cardiovascular aging; 12-year follow-up
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| All-cause deaths | 28% fewer in the treated group as reported | |
| Cardiovascular mortality | Twofold lower as reported | |
| Cardiovascular failure and respiratory disease incidence | Twofold lower as reported |
No sample size, event counts or confidence intervals are supplied in the abstract. These are Epithalamin extract findings, not synthetic Epitalon results.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Older patients with coronary disease and accelerated cardiovascular aging; 12-year follow-up
- Source reviewed
- Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
- The abstract leaves group assignment and follow-up unclear and gives no absolute event counts.
- Potential overlap with later follow-up reports must be checked; this is not an Epitalon trial.
Reviewed 2026-09-29.
Explore related historical combinations ↗
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗